Mesoblast appoints Lyn Cobley to its Board of Directors, plans to expand cell therapy products

From GlobeNewswire: 2025-04-28 19:44:00

Mesoblast appoints Lyn Cobley to its Board of Directors, a global financial leader with over 30 years of experience in senior positions at international and domestic banks. Ms. Cobley’s appointment follows the recent FDA approval of Ryoncil®, positioning Mesoblast as a global leader in allogeneic cell therapy. The company plans to ramp up commercialization and explore additional indications for inflammatory diseases. Mesoblast’s RYONCIL® is the first FDA-approved mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft versus host disease. The company is committed to developing cell therapies for various indications and has a strong global intellectual property portfolio extending through 2041.



Read more at GlobeNewswire: Mesoblast Appoints Corporate Finance Leader Lyn Cobley To